MX2013008340A - Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. - Google Patents

Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.

Info

Publication number
MX2013008340A
MX2013008340A MX2013008340A MX2013008340A MX2013008340A MX 2013008340 A MX2013008340 A MX 2013008340A MX 2013008340 A MX2013008340 A MX 2013008340A MX 2013008340 A MX2013008340 A MX 2013008340A MX 2013008340 A MX2013008340 A MX 2013008340A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
hdac inhibitors
benzamides
hydroxy
Prior art date
Application number
MX2013008340A
Other languages
English (en)
Inventor
Guozhi Tang
Xianfeng Lin
Zongxing Qiu
Jason Christopher Wong
Zhenshan Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013008340A publication Critical patent/MX2013008340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención proporciona compuestos de la fórmula (ver Fórmula) o sus sales ésteres o estereoisómeros farmacéuticos aceptables, en donde R1 a R4, A e Y tienen los significados dados aquí, así como métodos para producir estos compuestos y su uso como medicamento, en particular como medicamento para el tratamiento de cáncer.
MX2013008340A 2011-01-21 2012-01-18 Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. MX2013008340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011070464 2011-01-21
PCT/EP2012/050665 WO2012098132A1 (en) 2011-01-21 2012-01-18 Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2013008340A true MX2013008340A (es) 2013-08-27

Family

ID=45497996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008340A MX2013008340A (es) 2011-01-21 2012-01-18 Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US8404738B2 (es)
EP (1) EP2665706B1 (es)
JP (1) JP5778297B2 (es)
KR (1) KR101569261B1 (es)
BR (1) BR112013017362A2 (es)
CA (1) CA2823780A1 (es)
ES (1) ES2525569T3 (es)
HK (1) HK1185874A1 (es)
MX (1) MX2013008340A (es)
RU (1) RU2591190C2 (es)
WO (1) WO2012098132A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
ES2862126T3 (es) * 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤による白血病の治療
TW201706265A (zh) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 做為Ｒｈｏ激酶（ＲＯＣＫ）抑制劑之內醯胺
AU2016288606A1 (en) * 2015-07-02 2018-01-18 Biomarin Pharmaceutical Inc. Histone deacetylase inhibtors
WO2018089651A1 (en) 2016-11-10 2018-05-17 Acetylon Pharmaceuticals, Inc. Phenyl and pyridinyl hydroxamic acids
ES2927352T3 (es) * 2017-01-10 2022-11-04 Cstone Pharmaceutical Suzhou Co Ltd Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos
ES2939730T3 (es) 2019-01-17 2023-04-26 Univ Lille Compuestos de heteroarilo de 5 miembros que contienen un resto hidroxamato y su uso
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307624A (pt) * 2002-03-13 2005-01-11 Janssen Pharmaceutica Nv Inibidores de histona desacetilase
US7705017B2 (en) 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
CA2576667A1 (en) 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
EP1861097A4 (en) * 2005-03-16 2010-01-13 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
SI2343286T1 (sl) 2006-10-28 2015-05-29 Methylgene Inc. Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
CA2690192A1 (en) * 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
CA2721218C (en) 2008-04-15 2015-03-24 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
WO2010009166A1 (en) * 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
WO2012075380A1 (en) * 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors

Also Published As

Publication number Publication date
EP2665706A1 (en) 2013-11-27
BR112013017362A2 (pt) 2016-10-04
JP2014502983A (ja) 2014-02-06
KR20130120517A (ko) 2013-11-04
KR101569261B1 (ko) 2015-11-13
CA2823780A1 (en) 2012-07-26
US20120190700A1 (en) 2012-07-26
RU2591190C2 (ru) 2016-07-10
US8404738B2 (en) 2013-03-26
JP5778297B2 (ja) 2015-09-16
RU2013136412A (ru) 2015-02-27
HK1185874A1 (zh) 2014-02-28
WO2012098132A1 (en) 2012-07-26
EP2665706B1 (en) 2014-10-22
ES2525569T3 (es) 2014-12-26

Similar Documents

Publication Publication Date Title
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
AU2012214029A8 (en) Rorgammat inhibitors
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
UA111770C2 (uk) Інгібітори бромдомену
PH12015500719A1 (en) Gdf-8-inhibitors
IN2015DN01156A (es)
IN2014MN02598A (es)
IN2015DN01119A (es)
PH12015500260A1 (en) Neprilysin inhibitors
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MY165087A (en) Neprilysin inhibitors
MY177344A (en) Compounds and their methods of use
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
IN2014MN02106A (es)
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2016006336A (es) Compuestos pirazolopirimidina.
EA201390381A1 (ru) Триазиноксадиазолы
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
IN2012DN03182A (es)
IN2015DN01151A (es)
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.

Legal Events

Date Code Title Description
FG Grant or registration